Business•
AbbVie Deal Signals Growing Pharma Interest in Psychedelics
AbbVie's $1.2 billion deal for a depression asset is signaling a major shift, with large pharmaceutical firms now seriously eyeing the psychedelic therapeutics market.
Anna Kuznetsov
Anna Kuznetsov is a health and science correspondent for Archeonis, specializing in the pharmaceutical industry, biotechnology, and healthcare policy. She covers clinical trials, regulatory affairs, and market trends.
1 Articles
11 Total Views
Joined September 2025
Languages
English
Areas of Expertise
Pharmaceutical IndustryBiotechnologyHealthcare PolicyClinical Trials
Latest Articles by Anna Kuznetsov